Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × Neoplasms × tovorafenib × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Interventional 1 Expanded_access 1

Sponsor

Cancer Type

Conditions

Neoplasms 1 Glioma 1

Interventions

Bone Marrow Transplantation 2 3-Iodobenzylguanidine 2 vorasidenib 1 tucatinib 1 tovorafenib 1 taletrectinib 1 olaparib 1 nirogacestat 1 glucarpidase 1 enzalutamide 1 denileukin diftitox 1 copanlisib 1 balstilimab 1 atezolizumab 1 adagrasib 1 Proton Pump Inhibitors 1 Peripheral Blood Stem Cell Transplantation 1 Nivolumab 1 LY3023414 1 Hydrocortisone 1 Crizotinib 1 Carboxypeptidases 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05760586 2024-08-12

Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

Day One Biopharmaceuticals, Inc.

Approved for marketing

Glioma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡